ClinicalTrials.gg
RecruitingNCT05348876Updated Nov 5, 2026

A Study to Learn More About How Safe Darolutamide is and How Well it Works Under Real World Conditions When Taken in Addition to Standard Androgen Deprivation Therapy (ADT) in Indian Participants With High-risk Non-metastatic Castration-resistant Prostate Cancer (nmCRPC)

A Phase 4 interventional study of Darolutamide (Nubeqa, BAY1841788) in Non-metastatic Castration-resistant Prostate Cancer, sponsored by Bayer. Recruiting at 15 sites in India. Open to male participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-05.

Sponsored by Bayer · Phase 4, Interventional, and Treatment

From the registry’s dates

  • Started Aug 2022; still recruiting 4 years 3 months later.
Updated Nov 5, 2026Site recruiting status changedPrimary completion moved+3 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
50
Allocation
Not applicable
Ages
18 Years and older
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 59 studies testing darolutamide in Prostatic Neoplasms — 29 open to participants now, 40 under way, 10 of them phase 3. darolutamide · Prostatic Neoplasms.

Planned enrollment
42nd of 59
50 · median 80
Started
2022
with 4 others
Phase 4
4 of 59
3 open now
Primary completion
2027-12
later than 21 of 39 live
Registered
29th of 59
by date
Lead sponsor
10 of 59
Bayer

Among the 59 studies testing darolutamide in Prostatic Neoplasms, this one is the 42nd largest by planned enrollment, is one of 5 that started in 2022, is one of 4 in phase 4, reaches primary completion later than 21 of the 39 other live ones, and was the 29th registered.

Prostatic Neoplasms

7,052 studies on the registry are indexed under Prostatic Neoplasms; 1,583 are open to participants now.

Browse Prostatic Neoplasms studies →

Open to participants now

29 of the 59 studies testing darolutamide in Prostatic Neoplasms are open now, in 12 countries. Recruiting first, the newest first:

23 more — sign in →

By country, each count listing its studies:

All 29 open studies →

About darolutamide

darolutamide: first FDA approval 2019 (NUBEQA), first EMA approval 2020. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,231 Prostatic Neoplasms studies recruiting now, 930 (76%) set no upper age limit and 76 (6%) stop at 75 or younger; 67 take children under 18; 82 take healthy volunteers.

This study: 18 Years and older · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 59 studies testing darolutamide in Prostatic Neoplasms, or all of them as a file.
02

Study summary

Researchers are looking for a better way to treat men who have non-metastatic castration-resistant prostate cancer (nmCRPC). This is a type of cancer of the prostate that has not yet spread to other parts of the body and that keeps progressing even when the amount of male sex hormones like testosterone (also called androgens) is reduced to very low levels. To reduce androgen levels in prostate cancer patients, androgen deprivation therapy (ADT) is often used. As androgens stimulate the growth of prostate cancer cells, low levels are needed to reduce or slow the growth of these tumors.

In men with nmCRPC, the cancer worsens despite low testosterone levels (also called castration resistant).

Prostate-specific antigen (PSA) is a protein that is made by both normal cells and by cancerous cells in the body. Thus, PSA levels can be taken as a marker for prostate cancer development.

Men with nmCRPC usually have higher levels of (PSA) than normal. They are considered "high risk" if they show signs of quickly increasing PSA levels as this could mean that the tumor is growing and might spread to other parts of the body.

The study treatment darolutamide is already available in certain countries for doctors to prescribe to men with prostate cancer that has not yet spread to other parts of the body. It works by blocking androgens from attaching to proteins in cancer cells in the prostate.

Results of a previous study in men with high-risk nmCRPC who received darolutamide in addition to ADT are already available, but this study had no Indian patients and was not conducted in India.

Therefore, the main purpose of this study is to learn how safe darolutamide is when taken in addition to ADT in Indian participants with high-risk nmCRPC.

To answer this question, the researchers will collect all medical problems the participants have that arise during the study and that may or may not be related to the study treatment. These medical problems are also known as "adverse events" (AE). The following information regarding safety of darolutamide will be collected during the study:

  • the number and severity of AEs that are non-serious or serious
  • the number of participants who have to permanently stop the treatment due to AEs
  • the number of participants who have to change the amount of study drug taken due to AEs

AEs can be:

  • abnormal results of laboratory tests, physical examinations, or heart health examinations using ECG (detects heart problems by measuring the electrical activity generated by the heart as it contracts).
  • relevant changes in vital signs
  • relevant changes of the participant's daily living abilities (ECOG performance status)

These results will then be compared with the results from the previous study to identify any differences for this group of participants.

In addition, researchers will collect and compare data on how well darolutamide worked under real world conditions in this group of participants.

All participants will take darolutamide as tablets by mouth twice a day. The participants will visit the study center at the start of the study, and then every 16 weeks until their cancer gets worse, they develop medical problems, they leave the study or until the study is terminated.

During the study, the study team will

  • take blood and urine samples
  • do physical examinations
  • check vital signs
  • examine heart health using ECG
  • assess the participant's ECOG performance status
  • ask the participants questions about how they are feeling and what AEs they are having.

If the trial is stopped, participants may have the option to continue to receive darolutamide, provided they benefit from the treatment

03

Conditions studied

  • Non-metastatic Castration-resistant Prostate Cancer

Browse trials for

Keywords

  • Prostate cancer
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Capable of giving signed .
  • Participant must be male aged ≥ 18 years.
  • or cytologically confirmed adenocarcinoma of prostate without neuroendocrine differentiation or small cell features.
  • Castration resistance, demonstrated by:

    • a minimum of 3 rising PSA values while the participant is on continuous ADT (started at least 4 weeks prior to the PSA measurement or, PSA measured at least 4 weeks after bilateral orchiectomy) and
    • the interval between each PSA measurement must be ≥ 1 week, and
    • the PSA value at screening must be ≥ 1.0 ng/mL (1.0 μg/L). To confirm this eligibility criterion, it is acceptable for 2 out of the 3 PSA measurements to be taken during the 28-day screening period (after participant has signed consent), provided the measurements are ≥ 1 week apart. In this case, the last PSA value should be recorded as the screening value.
  • Castrate level of serum testosterone (\< 1.7 nmol/L [50 ng/dL]) on gonadotropin releasing hormone (GnRH) agonist or antagonist therapy or after bilateral orchiectomy. Participants who have not undergone bilateral orchiectomy must continue GnRH therapy during the study.
  • PSA doubling time (PSADT) of ≤ 10 months.
  • (ECOG) performance status (PS) of 0 or 1.
  • Estimated (eGFR) > 15 mL/min/1.73 m\^2.
  • Blood counts at screening: ≥ 9.0 g/dL, ≥ 1500/μL (1.5 × 109/L), count ≥ 100,000/μL (100 ×109/L) (participant must not have received any growth factor or blood transfusion within 7 days of the hematology laboratory obtained at screening).
  • Screening values of serum (ALT) and aspartate transaminase (AST) ≤ 2.5 × (ULN), total (TBL) ≤ 1.5 × ULN (except participants with a diagnosis of Gilbert's disease), creatinine ≤ 2.0 × ULN.
  • Sexually active participants, unless surgically sterile, must agree to use a male condom plus partner use of a method with a failure rate of \<1% per year, and refrain from sperm donation during the study treatment and for 1 week after the last dose of study treatment. Contraceptive use by men should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies.

Exclusion criteria

Exclusion Criteria:

  • History of disease at any time or presence of detectable metastases by investigator assessment within 42 days prior to start of study treatment based on standard medical imaging, i.e., computed tomography/ magnetic resonance imaging (CT/MRI) and bone scan. (Lesions seen on prostate-specific membrane antigen /positron emission tomography (PSMA/PET) scan that are not detected on standard imaging do not exclude participation.) Presence of pelvic lymph nodes \< 1.5 cm in short axis below the aortic bifurcation is allowed.
  • Symptomatic local-regional disease that requires medical intervention including moderate/severe urinary obstruction or hydronephrosis due to prostate cancer.
  • Acute toxicities of prior treatments and procedures not resolved to (CTCAE) v.5.0 grade ≤ 1 or baseline before first dose of study treatment.
  • Severe or uncontrolled concurrent disease, infection, or co-morbidity that, in the opinion of the investigator, would make the participant inappropriate for enrollment.
  • Known to the study treatment or any of its ingredients.
  • Major surgery within 28 days before first dose of study treatment.
  • Any of the following within 6 months before first dose of study treatment: stroke, myocardial infarction, severe/unstable angina pectoris, coronary/peripheral artery bypass graft; congestive heart failure Class III or IV.
  • Uncontrolled hypertension as indicated by a systolic blood pressure (BP) ≥ 160 mmHg or diastolic BP ≥ 100 mmHg at screening despite medical management. Participants with hypertension can enroll provided BP is stable and controlled by anti-hypertensive treatment.
  • End-stage renal disease ( \< 15 mL/min/1.73 m\^2).
  • Prior . Adequately treated basal cell or squamous cell carcinoma of skin or superficial bladder cancer that has not spread behind the connective tissue layer (i.e., pTis, pTa, and pT1) is allowed, as well as any other cancer for which treatment has been completed ≥ 5 years ago and from which the participant has been disease-free.
  • Gastrointestinal disorder or procedure which expects to interfere significantly with absorption of study treatment.
  • Unstable active viral hepatitis with a need for treatment.
  • Known (HIV) infection with any of the following (Note: HIV testing is not required unless mandated by local authority):

    • CD4+ T-cell (CD4+) count of less than 350 cells/μL
    • History of acquired immunodeficiency syndrome (AIDS)-defining opportunistic infection within the past 12 months
    • On established antiretroviral therapy for less than 4 weeks
    • Presenting with a viral load of more than 400 copies/mL prior to enrollment
    • On antiretroviral therapy or prophylactic antimicrobials that are expected to cause significant drug-drug interactions or overlapping toxicities with study treatment and cannot be changed to alternative agents.
  • Any condition that, in the opinion of the investigator, would impair the participants' ability to comply with the study procedures or study treatment (e.g., unable to swallow study treatment).
  • Unwilling or unable to comply with all protocol-required visits and assessments or comply with study requirements.
  • Prior treatment with:

    • Second-generation androgen receptor (AR) inhibitors (such as enzalutamide, apalutamide, darolutamide, proxalutamide, etc)
    • Other AR inhibitors
    • Cytochrome P450 (CYP17) enzyme inhibitors (such as oral ketoconazole, abiraterone acetate, TAK-700, etc).
  • Use of first-generation AR inhibitors (bicalutamide, flutamide, nilutamide, cyproterone acetate) within 28 days before first dose of study treatment.
  • Use of estrogens or 5-α reductase inhibitors (finasteride, dutasteride) within 28 days before first dose of study treatment.
  • Prior chemotherapy or immunotherapy for prostate cancer, except /neoadjuvant treatment completed > 2 years before first dose of study treatment.
  • Use of systemic with dose greater than the equivalent 10 mg of prednisone/day within 28 days before first dose of study treatment.
  • Radiation therapy (external beam radiation therapy, brachytherapy, or radiopharmaceuticals) within 12 weeks before first dose of study treatment.
  • Treatment with an osteoclast-targeted therapy (bisphosphonate or denosumab) to prevent skeletal-related events within 4 weeks before first dose of study treatment. Participants receiving osteoclast-targeted therapy to prevent bone loss at a dose and schedule indicated for osteoporosis may continue treatment at the same dose and schedule.
  • Treatment with any investigational drug within 28 days before first dose of study treatment.
Terms in these criteria, in plain language(20)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
50 participants (estimated)

Study arms

  • Experimental
    Darolutamide (BAY1841788)

    Participants with high-risk nmCRPC will receive darolutamide.

    Drug: Darolutamide (Nubeqa, BAY1841788)

Interventions

  • 600 mg (two 300 mg) tablets of darolutamide to be taken orally twice a day at about 12-hour intervals, equivalent to a total daily dose of 1200 mg.

06

What researchers measure

Primary outcomes

  1. Number of participants with adverse events (AEs) and serious adverse events (SAEs) and their severity.

    Time frame: Approximately 15 months.

  2. Number of participants with discontinuations of study treatment due to AEs

    Time frame: Approximately 15 months

  3. Number of participants with dose modifications of study treatment due to AEs

    Time frame: Approximately 15 months

  4. Number of participants with clinically significant abnormalities in laboratory parameters

    Time frame: Approximately 15 months

  5. Number of participants with clinically significant electrocardiograms abnormalities

    Time frame: Approximately 15 months

  6. Number of participants with clinically significant physical examination abnormalities

    Time frame: Approximately 15 months

  7. Number of participants with clinically significant changes in vital signs

    Time frame: From baseline to approximately 15 months

  8. Number of participants with changes in eastern cooperative oncology group (ECOG) performance status

    Time frame: From baseline to approximately 15 months

Secondary outcomes

  1. Prostate-specific antigen (PSA) percent change from baseline to 16 weeks

    Time frame: From baseline to 16 weeks

  2. PSA maximum percent decline from baseline at any time on study treatment

    Time frame: From baseline to approximately 15 months

  3. Time to initiation of first subsequent systemic antineoplastic therapy

    Time frame: At approximately 15 months

  4. Time to initiation of first cytotoxic chemotherapy for prostate cancer

    Time frame: At approximately 15 months

07

Study locations

11 of 15 sites recruiting
  • Muljibhai Patel Urological Hospital (MPUH) (Kidney Hospital)
    Nadiād, Gujarat 387001, India
    Recruiting
  • HCG Oncology Center
    Bengaluru, Karnataka 560027, India
    Recruiting
  • Amrita Institute of Medical Sciences
    Kochi, Kerala 682041, India
    Recruiting
  • Regional Cancer Centre - Thiruvananthapuram
    Thiruvananthapuram, Kerala 695011, India
    Recruiting
  • MVR Cancer Centre and Research Institute
    Vellalasseri, Kerala 673601, India
    Recruiting
  • Sujan Surgical Cancer Hospital & Amravati Cancer Foundation
    Amravati, Maharashtra 444605, India
    Active, not recruiting

    Not enrolling at this site.

  • Tata Memorial Hospital
    Mumbai, Maharashtra 400012, India
    Recruiting
  • Dr. RML Hospital & PGIMER
    New Delhi, National Capital Territory of Delhi 110001, India
    Completed

    Not enrolling at this site.

  • Rajiv Gandhi Cancer Institute & Research Centre
    New Delhi, National Capital Territory of Delhi 110085, India
    Recruiting
  • All India Institute of Medical Sciences
    Bhubaneswar, Odisha 751019, India
    Recruiting
  • Jawaharlal Institute Of Postgraduate Medical Education and R
    Gorimedu, Puducherry 605006, India
    Not yet recruiting
  • Bhagwan Mahaveer Cancer Hospital & Research Centre
    Jaipur, Rajasthan 302017, India
    Recruiting
  • Apollo Research Foundation
    Hyderabad, Telangana 500096, India
    Not yet recruiting
  • Mahamana Pandit Madan Mohan Malviya Cancer Centre
    Varanasi, Uttar Pradesh 221005, India
    Recruiting
  • Netaji Subhas Chandra Bose Cancer Hospital
    Kolkata, West Bengal 700094, India
    Recruiting
08

References and documents

Individual participant data

Plan to share: No — Availability of this study's data will later be determined according to Bayer's commitment to the EFPIA/PhRMA "Principles for responsible clinical trial data sharing". This pertains to scope, timepoint and process of data access. As such, Bayer commits to sharing upon request from qualified researchers patient-level clinical trial data, study-level clinical trial data, and protocols from clinical trials in patients for medicines and indications approved in the US and EU as necessary for conducting legitimate research. This applies to data on new medicines and indications that have been approved by the EU and US regulatory agencies on or after January 01, 2014. Interested researchers can use www.vivli.org to request access to anonymized patient-level data and supporting documents from clinical studies to conduct research. Information on the Bayer criteria for listing studies and other relevant information is provided in the member section of the portal.

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2022 (actual). Primary completion is estimated for Dec 2027, 64 months after the start.

Of 52 phase 4 interventional studies under Prostatic Neoplasms, half reached primary completion within 40 months of starting (the median), counting those still running; a quarter within 28 and three quarters within 67. This study's planned 64 months is above that.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 5, 2026: primary completion Apr 2027 → Dec 2027 and completion Apr 2027 → Dec 2027.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Apr 21, 2022
First posted
Apr 27, 2022
StartActual
Aug 3, 2022
Primary completionEst.
Dec 30, 2027was Apr 2027
CompletionEst.
Dec 30, 2027was Apr 2027
Last update
Nov 5, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
10 sites removed. 6 sites changed recruiting status (3 now recruiting, 2 now not yet recruiting, …)
Show 6 sites
  • Muljibhai Patel Urological Hospital (MPUH) (Kidney Hospital) · Nadiād, IndiaCompleted→Recruiting
  • HCG Oncology Center · Bengaluru, IndiaCompleted→Recruiting
  • Sujan Surgical Cancer Hospital & Amravati Cancer Foundation · Amravati, IndiaCompleted→Active, not recruiting
  • Jawaharlal Institute Of Postgraduate Medical Education and R · Gorimedu, IndiaCompleted→Not yet recruiting
  • Bhagwan Mahaveer Cancer Hospital & Research Centre · Jaipur, IndiaCompleted→Recruiting
  • Apollo Research Foundation · Hyderabad, IndiaCompleted→Not yet recruiting
Show 10 removed
  • HCG-City Cancer Centre · Vijayawada, India
  • King George Hospital · Visakhapatnam, India
  • Surat Institute of Digestive Sciences · Surat, India
  • KLES Dr. Prabhakar Kore Hospital & Medical Research Centre · Belagavi, India
  • Fortis Hospital Bangalore · Bengaluru, India
  • Bangalore Medical College and Research Institute (BMCRI) - Victoria Hospital · Bangalore, India
  • Dayanand Medical College & Hospital · Ludhiana, India
  • Erode Cancer Centre · Erode, India
  • MNJ Institute of Oncology & Regional Cancer Centre · Hyderabad, India
  • Post Graduate Institute of Medical Education and Research · Chandigarh, India
Nov 5, 2026
Primary completion
Apr 29, 2027→Dec 30, 2027
Nov 5, 2026
Study completion
Apr 29, 2027→Dec 30, 2027
Nov 5, 2026
Eligibility
Revised
Nov 5, 2026
Show all 1 update
  1. Nov 5, 2026
    10 sites removed. 6 sites changed recruiting status (3 now recruiting, 2 now not yet recruiting, …)
    Show 6 sites
    • Muljibhai Patel Urological Hospital (MPUH) (Kidney Hospital) · Nadiād, IndiaCompleted→Recruiting
    • HCG Oncology Center · Bengaluru, IndiaCompleted→Recruiting
    • Sujan Surgical Cancer Hospital & Amravati Cancer Foundation · Amravati, IndiaCompleted→Active, not recruiting
    • Jawaharlal Institute Of Postgraduate Medical Education and R · Gorimedu, IndiaCompleted→Not yet recruiting
    • Bhagwan Mahaveer Cancer Hospital & Research Centre · Jaipur, IndiaCompleted→Recruiting
    • Apollo Research Foundation · Hyderabad, IndiaCompleted→Not yet recruiting
    Show 10 removed
    • HCG-City Cancer Centre · Vijayawada, India
    • King George Hospital · Visakhapatnam, India
    • Surat Institute of Digestive Sciences · Surat, India
    • KLES Dr. Prabhakar Kore Hospital & Medical Research Centre · Belagavi, India
    • Fortis Hospital Bangalore · Bengaluru, India
    • Bangalore Medical College and Research Institute (BMCRI) - Victoria Hospital · Bangalore, India
    • Dayanand Medical College & Hospital · Ludhiana, India
    • Erode Cancer Centre · Erode, India
    • MNJ Institute of Oncology & Regional Cancer Centre · Hyderabad, India
    • Post Graduate Institute of Medical Education and Research · Chandigarh, India
    Primary completion Apr 29, 2027→Dec 30, 2027
    Study completion Apr 29, 2027→Dec 30, 2027
    Eligibility Revised
    + 2 other changes: verification date and contact details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT05348876
Lead sponsor
Bayer
Responsible party
Sponsor
First posted
Apr 27, 2022
Start date
Aug 3, 2022
Primary completion
Dec 30, 2027 (estimated)
Completion
Dec 30, 2027 (estimated)
Last update
Nov 5, 2026

Study contacts

Bayer Clinical Trials Contact
Contact
clinical-trials-contact@bayer.com
18888422937

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Darolutamide

Start the discussion